Drug guidance
Ezetimibe and ezetimibe/simvastatin for treating primary hypercholesterolaemia
Condition
Cardiovascular
2 May 2019
Published on 02 May 2019
Last Updated on 02 May 2019
Guidance Recommendations
The Ministry of Health's Drug Advisory Committee has recommended:
Ezetimibe 10 mg tablet for treating primary (heterozygous familial and non-familial) hypercholesterolaemia in adults as:
Add-on therapy to statins when the cholesterol concentration therapeutic target is not achieved at the maximum tolerated statin dose; or
Monotherapy as an alternative to statins for adults who are intolerant of, or contraindicated to, statin therapy.
Intolerance to statin therapy is defined as the occurrence of clinically significant adverse effects that are an unacceptable risk to the patient.
Subsidy status
Ezetimibe 10 mg tablet is recommended for inclusion on the MOH Standard Drug List (SDL) for the abovementioned indications.
SDL subsidy does not apply to ezetimibe/simvastatin 10/10 mg or 10/20 mg tablets.